Westphal LM, Polan ML, Trant AS
Here are key insights from those discussions: Anecdotal Evidence and Mechanism : BPC-157 is noted for its potential to enhance tissue recovery and angiogenesis (blood vessel growth) based on animal studies, but human clinical data is limited
121 Treatment with CRMs has been found to decrease the concentration of free IGF-1, promote autophagy in cancer cells, and improve the antitumor immune response, resulting in a reduction in tumor growth when combined with immunogenic chemotherapeutics
Rao M, Gao C, Hou J, Gu J, Law BYK, Xu Y
Goal-Specific Dosing Considerations The optimal MOTS-c dose is not one-size-fits-all: it shifts depending on whether the clinical goal is metabolic correction, athletic performance enhancement, or anti-aging and longevity support